Cargando…

Myeloid-derived suppressor cells in gliomas

Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of early myeloid progenitors and precursors at different stages of differentiation into granulocytes, macrophages, and dendritic cells. Blockade of their differentiation into mature myeloid cells in cancer results in an expansio...

Descripción completa

Detalles Bibliográficos
Autores principales: Gieryng, Anna, Kaminska, Bozena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5371700/
https://www.ncbi.nlm.nih.gov/pubmed/28373814
http://dx.doi.org/10.5114/wo.2016.64592
_version_ 1782518473646145536
author Gieryng, Anna
Kaminska, Bozena
author_facet Gieryng, Anna
Kaminska, Bozena
author_sort Gieryng, Anna
collection PubMed
description Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of early myeloid progenitors and precursors at different stages of differentiation into granulocytes, macrophages, and dendritic cells. Blockade of their differentiation into mature myeloid cells in cancer results in an expansion of this population. High-grade gliomas are the most common malignant tumours of the central nervous system (CNS), with a poor prognosis despite intensive radiation and chemotherapy. Histopathological and flow cytometry analyses of human and rodent experimental gliomas revealed the extensive heterogeneity of immune cells infiltrating gliomas and their microenvironment. Immune cell infiltrates consist of: resident (microglia) and peripheral macrophages, granulocytes, myeloid-derived suppressor cells, and T lymphocytes. Intratumoural density of glioma-associated MDSCs correlates positively with the histological grade of gliomas and patient’s survival. MDSCs have the ability to attract T regulatory lymphocytes to the tumour, but block the activation of tumour-reactive CD4(+) T helper cells and cytotoxic CD8(+) T cells. Immunomodulatory mechanisms employed by malignant gliomas pose an appalling challenge to brain tumour immunotherapy. In this mini-review we describe phenotypic and functional characteristics of MDSCs in humans and rodents, and their occurrence and potential roles in glioma progression. While understanding the complexity of immune cell interactions in the glioma microenvironment is far from being accomplished, there is significant progress that may lead to the development of immunotherapy for gliomas.
format Online
Article
Text
id pubmed-5371700
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Termedia Publishing House
record_format MEDLINE/PubMed
spelling pubmed-53717002017-04-03 Myeloid-derived suppressor cells in gliomas Gieryng, Anna Kaminska, Bozena Contemp Oncol (Pozn) Review Paper Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of early myeloid progenitors and precursors at different stages of differentiation into granulocytes, macrophages, and dendritic cells. Blockade of their differentiation into mature myeloid cells in cancer results in an expansion of this population. High-grade gliomas are the most common malignant tumours of the central nervous system (CNS), with a poor prognosis despite intensive radiation and chemotherapy. Histopathological and flow cytometry analyses of human and rodent experimental gliomas revealed the extensive heterogeneity of immune cells infiltrating gliomas and their microenvironment. Immune cell infiltrates consist of: resident (microglia) and peripheral macrophages, granulocytes, myeloid-derived suppressor cells, and T lymphocytes. Intratumoural density of glioma-associated MDSCs correlates positively with the histological grade of gliomas and patient’s survival. MDSCs have the ability to attract T regulatory lymphocytes to the tumour, but block the activation of tumour-reactive CD4(+) T helper cells and cytotoxic CD8(+) T cells. Immunomodulatory mechanisms employed by malignant gliomas pose an appalling challenge to brain tumour immunotherapy. In this mini-review we describe phenotypic and functional characteristics of MDSCs in humans and rodents, and their occurrence and potential roles in glioma progression. While understanding the complexity of immune cell interactions in the glioma microenvironment is far from being accomplished, there is significant progress that may lead to the development of immunotherapy for gliomas. Termedia Publishing House 2016-12-20 2016 /pmc/articles/PMC5371700/ /pubmed/28373814 http://dx.doi.org/10.5114/wo.2016.64592 Text en Copyright: © 2016 Termedia Sp. z o. o. http://creativecommons.org/licenses/by-nc-sa/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
spellingShingle Review Paper
Gieryng, Anna
Kaminska, Bozena
Myeloid-derived suppressor cells in gliomas
title Myeloid-derived suppressor cells in gliomas
title_full Myeloid-derived suppressor cells in gliomas
title_fullStr Myeloid-derived suppressor cells in gliomas
title_full_unstemmed Myeloid-derived suppressor cells in gliomas
title_short Myeloid-derived suppressor cells in gliomas
title_sort myeloid-derived suppressor cells in gliomas
topic Review Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5371700/
https://www.ncbi.nlm.nih.gov/pubmed/28373814
http://dx.doi.org/10.5114/wo.2016.64592
work_keys_str_mv AT gierynganna myeloidderivedsuppressorcellsingliomas
AT kaminskabozena myeloidderivedsuppressorcellsingliomas